LOXL2 and neoplasm: Utilizing a novel in-house assay,30 we observed a significant reduction in tumor LOXL2 activity in PXS-5505-treated cohorts, providing evidence of sustained drug delivery and target engagement (Supplemental methods, supplemental Figure S9, http://links.lww.com/HC9/A993).